Cingulate Inc. financial data

Symbol
CING, CINGW on Nasdaq
Industry
Pharmaceutical Preparations
Location
1901 W. 47 Th Place, Kansas City, KS
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 107 % +96.2%
Debt-to-equity 141 %
Return On Equity -570 % -115%
Return On Assets -236 % +17.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.21M shares -82.9%
Common Stock, Shares, Outstanding 3.04M shares -82.5%
Entity Public Float 7.8M USD -32.2%
Common Stock, Value, Issued 305 USD -82.5%
Weighted Average Number of Shares Outstanding, Basic 1.77M shares +2045%
Weighted Average Number of Shares Outstanding, Diluted 1.77M shares +2045%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 10.1M USD -18.8%
General and Administrative Expense 6.13M USD -23.3%
Operating Income (Loss) -16.2M USD +20.6%
Nonoperating Income (Expense) -115K USD +85.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -16.3M USD +22.9%
Net Income (Loss) Attributable to Parent -16.3M USD +22.9%
Earnings Per Share, Basic -1.83 USD/shares +97.5%
Earnings Per Share, Diluted 52.6 USD/shares +97.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10M USD +405%
Assets, Current 11.3M USD +291%
Property, Plant and Equipment, Net 2.07M USD -18.4%
Operating Lease, Right-of-Use Asset 170K USD -61.1%
Assets 13.6M USD +131%
Accounts Payable, Current 906K USD -45.8%
Accrued Liabilities, Current 402K USD -41.9%
Liabilities, Current 1.54M USD -73.1%
Operating Lease, Liability, Noncurrent 33.1K USD -91.8%
Liabilities 1.54M USD -74.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -3.25K USD
Retained Earnings (Accumulated Deficit) -102M USD -19%
Stockholders' Equity Attributable to Parent 12M USD
Liabilities and Equity 13.6M USD +131%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.75M USD -145%
Net Cash Provided by (Used in) Financing Activities 9.89M USD
Net Cash Provided by (Used in) Investing Activities -81.5K USD -119%
Common Stock, Shares Authorized 240M shares 0%
Common Stock, Shares, Issued 3.04M shares -82.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.06M USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 308 USD -44.5%
Deferred Tax Assets, Valuation Allowance 16.1M USD +46.7%
Deferred Tax Assets, Gross 13.2M USD +123%
Operating Lease, Liability 489K USD -41%
Depreciation 665K USD +32.9%
Payments to Acquire Property, Plant, and Equipment 81.5K USD +119%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.98M USD -48.6%
Property, Plant and Equipment, Gross 5.2M USD +4%
Operating Lease, Liability, Current 225K USD -36.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 6.52M USD +92.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 114M USD +33.2%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 564K USD +73%
Interest Expense 634K USD -83.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%